Karyopharm Therapeutics Inc.(KPTI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KPTI Karyopharm Therapeutics Inc.

交易中 05-14 15:54:21 EDT

9.03

+0.18

+2.03%

最高10.23	最低8.70	成交量89.65万
今开9.53	昨收8.85	日振幅17.29%
总市值2.04亿	流通市值1.93亿	总股本2,254万
成交额827.20万	换手率4.19%	流通股本2,140万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KPTI","market":"US","secType":"STK","nameCN":"Karyopharm Therapeutics Inc.","latestPrice":9.03,"timestamp":1778788459170,"preClose":8.85,"halted":0,"volume":896492,"delay":0,"changeRate":0.020338983050847425,"floatShares":21395200,"shares":22543300,"eps":-17.93,"marketStatus":"交易中","change":0.18,"latestTime":"05-14 15:54:21 EDT","open":9.525,"high":10.2299,"low":8.7,"amount":8272042.8490079995,"amplitude":0.17287,"askPrice":9.05,"askSize":700,"bidPrice":8.97,"bidSize":63,"shortable":3,"etf":0,"ttmEps":-17.93,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1778788800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1383714000000,"exchange":"NASDAQ","adjPreClose":8.85,"preHourTrading":{"tag":"盘前","latestPrice":9.48,"preClose":8.85,"latestTime":"09:29 EDT","volume":9114,"amount":86420.096364,"timestamp":1778765399999,"change":0.63,"changeRate":0.071186,"amplitude":0.090395},"postHourTrading":{"tag":"盘后","latestPrice":8.85,"preClose":8.85,"latestTime":"19:03 EDT","volume":1078,"amount":9541.23,"timestamp":1778713414720,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.10146,"impliedVol":2.2994,"impliedVolPercentile":0.6574},"requestUrl":"/m/hq/s/KPTI/tweets","defaultTab":"tweets","newsList":[{"id":"1188494010","title":"Karyopharm公布2026年第一季度财务业绩并完成子宫内膜癌三期试验患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1188494010","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188494010?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:31","pubTimestamp":1778758278,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc. (KPTI) 近日宣布了其2026年第一季度的财务业绩，并同步披露了一项关键临床进展：公司已成功完成其针对子宫内膜癌的三期临床试验的患者招募工作。\n这一进展标志着公司核心管线药物selinexor在拓展新适应症方面迈出了重要一步。子宫内膜癌是女性生殖系统常见的恶性肿瘤，此次三期试验的顺利完成，为后续获取关键疗效数据、寻求监管批准奠定了坚实基础。\n与此同时，公司公布的2026年第一季度财务数据，为投资者评估其当前运营状况与资金储备提供了最新依据。在推进多项后期临床研究的同时，公司的财务状况与研发里程碑共同构成了市场关注的核心焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196415628","title":"Karyopharm Therapeutics股价盘前飙升16%，其血癌药物在后期研究中达成两大主要目标之一","url":"https://stock-news.laohu8.com/highlight/detail?id=1196415628","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196415628?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:36","pubTimestamp":1774352204,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc.（股票代码：KPTI）股价在盘前交易中大幅上涨16%，此前该公司宣布其研发的一款血癌药物在一项关键后期研究中，成功达到了预设的两大主要目标之一。这一积极进展为药物的后续审批及商业化前景注入了强劲动力，显著提振了投资者信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KPTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116071082","title":"Karyopharm将与美国FDA会面 商讨Sentry试验数据及潜在sNDA申请事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1116071082","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116071082?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:02","pubTimestamp":1774350132,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc. 即将与美国食品药品监督管理局（FDA）举行会议，重点讨论其Sentry临床试验所获得的数据结果，以及后续提交补充新药申请（sNDA）的潜在可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KPTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185126516","title":"Karyopharm骨髓纤维化三期Sentry试验达成首个共同主要终点，脾脏体积缩小呈现统计学显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1185126516","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185126516?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:01","pubTimestamp":1774350093,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc.（纳斯达克代码：KPTI）宣布，其针对骨髓纤维化患者的三期Sentry临床试验已成功达到首个共同主要终点。数据显示，接受治疗的患者在脾脏体积缩小方面取得统计学上的显著改善。\n该突破性进展为骨髓纤维化治疗领域带来新的希望，标志着Karyopharm在血液恶性肿瘤治疗研发中迈出关键一步。研究人员将继续评估试验的第二个共同主要终点——总症状评分改善情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KPTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103779071","title":"Karyopharm Therapeutics修订融资条款 取消50%资金用于提升最低流动性要求的限制","url":"https://stock-news.laohu8.com/highlight/detail?id=1103779071","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103779071?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:06","pubTimestamp":1772535977,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc.近日宣布，已成功完成对其融资协议的修订。根据最新条款，公司取消了原有协议中要求将50%融资收益专项用于提高最低流动性承诺的规定。这一调整将为Karyopharm提供更灵活的资金运用空间，使其能够根据研发进展和商业需求更高效地配置资源。通过解除资金使用限制，Karyopharm可以更自主地决定将融资款项投入最具潜力的领域，包括创新药物研发、临床试验推进以及商业化布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KPTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101404919","title":"Karyopharm Therapeutics Inc. 修订协议允许公司延期付款至2026年9月——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1101404919","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101404919?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:04","pubTimestamp":1772535854,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的一份文件，Karyopharm Therapeutics Inc. 已通过一项修订协议，获得将特定款项的支付期限推迟至2026年9月的许可。此项安排为公司提供了更灵活的财务运营空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182268638","title":"Karyopharm公布2025年初步未经审计营收 并重申2026年有望发布变革性三期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1182268638","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182268638?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:02","pubTimestamp":1768219354,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc.今日披露了2025财年初步未经审计的营收预期，同时再度确认其核心研发管线将在2026年迎来关键节点。公司强调，届时公布的三期临床试验数据可能成为颠覆现有治疗格局的里程碑。尽管具体财务细节尚未完全公开，但此次预告凸显了公司对商业化进程与研发突破双线并进的战略信心。在生物技术板块波动加剧的背景下，Karyopharm通过明确时间表向投资者传递确定性。分析师指出，若三期数据符合预期，该企业有望在靶向治疗领域构建差异化竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149622364","title":"Karyopharm Therapeutics公布依据纳斯达克上市规则5635(C)(4)授予的引援股权奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=1149622364","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149622364?lang=zh_cn&edition=full","pubTime":"2026-01-03 06:25","pubTimestamp":1767392727,"startTime":"0","endTime":"0","summary":"1月2日——Karyopharm Therapeutics Inc宣布，公司已根据纳斯达克上市规则5635(C)(4)条款，向新入职员工授予了引援性股权激励。该举措旨在吸引高端人才加入企业团队，通过股权授予方式强化人才与企业发展的深度绑定。此次股权授予完全遵循纳斯达克相关监管要求，体现了公司治理的规范性与透明度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KPTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170067306","title":"Karyopharm Therapeutics公布根据纳斯达克上市规则5635(C)(4)的激励授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1170067306","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170067306?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:31","pubTimestamp":1763569862,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc：*KARYOPHARM THERAPEUTICS公布根据纳斯达克上市规则5635(C)(4)的激励授予。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102548974","title":"Karyopharm Therapeutics 第三季度净收入为负3312.7万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102548974","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102548974?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:28","pubTimestamp":1763569688,"startTime":"0","endTime":"0","summary":"11月3日 - Karyopharm Therapeutics 第三季度产品收入为3203.2万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518822073","title":"Karyopharm Therapeutics Inc.盘中异动 早盘股价大涨5.22%报7.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518822073","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518822073?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:19","pubTimestamp":1741616363,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时19分，Karyopharm Therapeutics Inc.股票出现波动，股价快速上涨5.22%。Karyopharm Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.35%。Karyopharm Therapeutics Inc.公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310221923abf30e51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310221923abf30e51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KPTI","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517944041","title":"Karyopharm Therapeutics Inc.盘中异动 临近午盘大幅跳水5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517944041","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517944041?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:43","pubTimestamp":1741193017,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时43分，Karyopharm Therapeutics Inc.股票出现异动，股价大幅跳水5.20%。Karyopharm Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为1.04%。Karyopharm Therapeutics Inc.公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306004337989d6422&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306004337989d6422&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KPTI","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516658033","title":"Karyopharm Therapeutics Inc.盘中异动 快速下跌5.09%报7.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658033","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516658033?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:53","pubTimestamp":1741017185,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时53分，Karyopharm Therapeutics Inc.股票出现异动，股价急速跳水5.09%。Karyopharm Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.38%。Karyopharm Therapeutics Inc.公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032353069637c0fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032353069637c0fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KPTI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516335036","title":"Baird：维持Karyopharm Therapeutics(KPTI.US)评级，由优于大市调整至优于大市评级, 目标价由75.00美元调整至54.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516335036","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516335036?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:51","pubTimestamp":1741006293,"startTime":"0","endTime":"0","summary":"Baird：维持Karyopharm Therapeutics(KPTI.US)评级，由优于大市调整至优于大市评级, 目标价由75.00美元调整至54.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03205148492763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["KPTI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516371793","title":"Karyopharm Therapeutics Inc.盘中异动 临近午盘急速下挫5.15%报7.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516371793","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516371793?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:46","pubTimestamp":1740761178,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时46分，Karyopharm Therapeutics Inc.股票出现波动，股价大幅下跌5.15%。Karyopharm Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.33%。Karyopharm Therapeutics Inc.公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030100461898969801&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030100461898969801&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514387366","title":"Karyopharm Therapeutics Inc.盘中异动 早盘大幅上涨5.49%报10.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514387366","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514387366?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:14","pubTimestamp":1740672884,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日00时14分，Karyopharm Therapeutics Inc.股票出现异动，股价快速上涨5.49%。截至发稿，该股报10.37美元/股，成交量10.3353万股，换手率1.23%，振幅9.36%。Karyopharm Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.57%。Karyopharm Therapeutics Inc.公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228001444a25693d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228001444a25693d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KPTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514859852","title":"Karyopharm Therapeutics Inc.盘中异动 股价大涨7.74%报9.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514859852","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514859852?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:38","pubTimestamp":1740580689,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时38分，Karyopharm Therapeutics Inc.股票出现波动，股价大幅上涨7.74%。截至发稿，该股报9.23美元/股，成交量1.793万股，换手率0.21%，振幅6.07%。Karyopharm Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.57%。Karyopharm Therapeutics Inc.公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262238099631506b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262238099631506b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","KPTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514893832","title":"HC Wainwright & Co.：维持Karyopharm Therapeutics(KPTI.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至56.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514893832","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514893832?lang=zh_cn&edition=full","pubTime":"2025-02-26 20:41","pubTimestamp":1740573703,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Karyopharm Therapeutics(KPTI.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至56.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26204148411567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["KPTI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514013593","title":"Karyopharm Therapeutics Inc.盘中异动 早盘股价大跌5.58%报0.562美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514013593","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514013593?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:51","pubTimestamp":1740495082,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时51分，Karyopharm Therapeutics Inc.股票出现波动，股价急速下跌5.58%。截至发稿，该股报0.562美元/股，成交量9.8686万股，换手率0.08%，振幅5.90%。Karyopharm Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为1.06%。Karyopharm Therapeutics Inc.公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022522512498925166&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022522512498925166&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513372732","title":"Karyopharm Therapeutics Inc.盘中异动 股价大跌9.76%报0.540美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513372732","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513372732?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:31","pubTimestamp":1740407467,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时31分，Karyopharm Therapeutics Inc.股票出现波动，股价急速下挫9.76%。截至发稿，该股报0.540美元/股，成交量33.4268万股，换手率0.26%，振幅0.00%。Karyopharm Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.12%。Karyopharm Therapeutics Inc.公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223107a25213eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223107a25213eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","KPTI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.karyopharm.com","stockEarnings":[{"period":"1week","weight":-0.0188},{"period":"1month","weight":0.0688},{"period":"3month","weight":-0.0101},{"period":"6month","weight":0.5581},{"period":"1year","weight":0.7988},{"period":"ytd","weight":0.2024}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0819},{"period":"3month","weight":0.0896},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.2649},{"period":"ytd","weight":0.0886}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Karyopharm Therapeutics Inc.于2008年12月22日在特拉华州注册成立。该公司是一家临床阶段的制药公司，专注于发现和开发针对核转运靶点的新型一线药物，用于治疗癌症和重大疾病。该公司的科学专长集中在了解细胞核和细胞质之间细胞内运输的调节。","yearOnYearQuotes":[{"month":1,"riseRate":0.307692,"avgChangeRate":-0.016},{"month":2,"riseRate":0.615385,"avgChangeRate":0.053911},{"month":3,"riseRate":0.538462,"avgChangeRate":0.020586},{"month":4,"riseRate":0.307692,"avgChangeRate":0.010096},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.035208},{"month":6,"riseRate":0.583333,"avgChangeRate":0.012026},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.027059},{"month":8,"riseRate":0.5,"avgChangeRate":0.051463},{"month":9,"riseRate":0.5,"avgChangeRate":-0.016173},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.041145},{"month":11,"riseRate":0.666667,"avgChangeRate":0.126143},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.06783}],"exchange":"NASDAQ","name":"Karyopharm Therapeutics Inc.","nameEN":"Karyopharm Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Karyopharm Therapeutics Inc.(KPTI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Karyopharm Therapeutics Inc.(KPTI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Karyopharm Therapeutics Inc.,KPTI,Karyopharm Therapeutics Inc.股票,Karyopharm Therapeutics Inc.股票老虎,Karyopharm Therapeutics Inc.股票老虎国际,Karyopharm Therapeutics Inc.行情,Karyopharm Therapeutics Inc.股票行情,Karyopharm Therapeutics Inc.股价,Karyopharm Therapeutics Inc.股市,Karyopharm Therapeutics Inc.股票价格,Karyopharm Therapeutics Inc.股票交易,Karyopharm Therapeutics Inc.股票购买,Karyopharm Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Karyopharm Therapeutics Inc.(KPTI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Karyopharm Therapeutics Inc.(KPTI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}